首页 > 市场调查报告书 > 医疗设备

体外诊断液体活检

市场调查报告书

商品编码

1297809

全球液体活检市场 - 2023-2030年

Global Liquid Biopsy Market - 2023-2030

出版日期: 2023年06月15日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

全球液体活检市场在2022年达到41亿美元，预计到2030年将见证有利可图的增长，达到123亿美元。在2023-2030年的预测期内，全球液体活检市场预计将呈现15.4%的复合增长率。

液体活检是一种非侵入性的诊断技术，可以分析体液中的生物标志物，提供对各种疾病（如癌症）的洞察力。与传统的组织活检相比，它具有优势，如更容易收集样本和实时监测疾病。

此外，全球癌症发病率的增加，基因组研究和技术的进步，越来越多地采用微创诊断程序，以及早期检测和监测疾病的潜力上升，预计将在预测期内推动市场发展。

市场动态

对患有实体癌的儿童进行液体活检的研究不断增加，预计将推动液体活检市场的增长

根据美国国家癌症研究所2023年的文章，癌症领域的研究人员正在液体活检测试的开发方面取得进展，这有可能补充甚至取代传统的组织活检。

这些测试分析肿瘤释放到血液和其他体液中的遗传和其他物质。目前，液体活检被用来检测与癌症有关的基因改变，并帮助治疗决策。

科学家们已经将液体活检的研究范围扩大到了癌症儿童，重点是实体瘤，如尤因肉瘤、骨肉瘤和威尔姆斯瘤（一种肾癌）。洛杉矶儿童医院（CHLA）和南加州大学的研究人员最近进行的一项研究在开发专门针对儿童癌症患者的液体活检测试方面取得了进展。

这种测试分析了在血液样本中发现的DNA片段，并在诊断儿童的各种类型的实体肿瘤方面显示出有希望的结果。发表在《npj Precision Oncology》上的这项研究还表明，这种检验在评估治疗反应和检测成功的初始治疗后可能的肿瘤复发方面具有潜力。

CHLA和南加州大学的研究人员开发的液体活检检验侧重于使用低通量全基因组测序检测拷贝数的改变。这种方法具有成本效益，可以同时分析多个样本。

虽然它也能检测到一些单核苷酸变化，但它不能检测到所有的变化。与许多正在为儿童开发的液体活检不同，这种方法和其他研究人员的类似测试旨在识别多种类型的癌症。因此，由于上述因素，该市场有望在预测期内得到推动。

诊断癌症的新工具不断发展，预计将推动液体活检市场增长

弗雷德-哈钦森癌症中心的计算生物学家Gavin Ha博士被授予2022年美国国家卫生研究院院长创新者奖。这笔150万美元的五年拨款将支持哈的研究，即利用液体活检中的无细胞肿瘤DNA来收集用于癌症诊断、治疗选择和疾病监测的宝贵信息。液体活检涉及分析血液样本中的DNA痕迹，提供对肿瘤的分子洞察力。

虽然大多数液体活检策略侧重于检测与癌症相关的DNA序列变化，但哈氏采取了一种不同的方法，研究使DNA片段在血液中持续存在的因素，特别是研究DNA包装蛋白提供的保护。我们细胞中的DNA被紧凑地包装起来，而这种包装在基因调控中起着作用。基因表达影响着癌细胞对治疗的反应，它们的抵抗模式，以及它们转化为不同癌细胞的潜力。

液体活检的技术挑战和限制阻碍了全球液体活检市场的发展

液体活检技术面临着各种技术挑战，这些挑战会限制其有效性并阻碍市场的增长。其中一些挑战包括敏感性和特异性、标准化和可重复性。

此外，监管和报销问题会阻碍液体活检测试的广泛采用。这些挑战包括监管部门的批准和报销政策。因此，从上述因素来看，预计在预测期内，市场将受到阻碍。

COVID-19影响分析

COVID-19大流行病对液体活检市场产生了重大影响。在大流行期间，包括癌症筛查和诊断程序在内的常规医疗访问有所减少。

因此，对液体活检测试的需求可能受到影响，因为这些测试通常被用作传统组织活检的非侵入性替代品。病人就诊和诊断测试的减少可能导致液体活检技术的总体采用和利用率下降。

此外，许多正在进行的与液体活检研究和开发有关的临床试验由于大流行病的影响而出现延误或中断。对病人招募的限制，对医疗设施的限制，以及对COVID-19管理资源的优先安排，导致了临床试验时间表的推迟或改变。这种研究活动的延迟会影响向市场推出新的液体活检技术和产品。

随着大流行病的发展和医疗系统的适应，液体活检市场预计将恢复并继续其增长轨迹，这是由技术、研究的进步和对个性化和无创癌症诊断的需求增加所推动的。

俄乌冲突分析

俄乌战争对各个领域都有影响，包括医疗行业和潜在的液体活检市场。这场战争对受影响地区的医疗基础设施造成了实质性的中断，特别是乌克兰。医疗设施的损坏、医疗供应的短缺和医疗人员的迁移都会中断医疗系统的常规运作。

由于资源被转用于满足更紧迫的医疗需求，这种中断可能会影响许多诊断测试的可用性和可及性，包括液体活检。此外，战争及其经济后果可能会改变医疗保健的支出和优先事项。由于预算有限，需要将资源分配给与战争有关的工作和冲突后的重建，可能会减少对医疗基础设施、研究和发展的投资。

持续的冲突会阻碍受影响地区的研究和发展工作。对资金和资源的限制，加上不稳定的研究环境，会减缓有关液体活检技术的创新和科学突破的进展。此外，在冲突中，与国际伙伴合作和交流知识和专长可能面临挑战。

Market Overview

The Global Liquid Biopsy Market reached US$ 4.1 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 12.3 billion by 2030. The Global Liquid Biopsy Market is expected to exhibit a CAGR of 15.4% during the forecast period 2023-2030.

Liquid biopsy is a non-invasive diagnostic technique that analyzes biomarkers in body fluids, providing insights into various diseases such as cancer. It offers advantages over traditional tissue biopsies, such as easier sample collection and real-time disease monitoring.

Furthermore, the increasing prevalence of cancer globally, advancements in genomic research and technology, increasing adoption of minimally invasive diagnostic procedures, and rising potential for early detection and monitoring of diseases are expected to drive the market over the forecast period.

Market Dynamics

Rising Research in Liquid Biopsies on the Horizon for Children with Solid Cancers is Expected to Drive Liquid Biopsy Market Growth

According to National Cancer Institute Article 2023, researchers in the field of cancer are making advancements in the development of liquid biopsy tests, which have the potential to complement or even replace traditional tissue biopsies.

These tests analyze genetic and other material released by tumors into the bloodstream and other bodily fluids. Currently, liquid biopsies are being utilized to detect cancer-related genetic alterations and aid in treatment decision-making.

Scientists have expanded their research on liquid biopsies to include children with cancer, focusing on solid tumors such as Ewing sarcoma, osteosarcoma, and Wilms tumor (a kidney cancer). A recent study conducted by researchers from Children's Hospital Los Angeles (CHLA) and the University of Southern California has made progress in developing a liquid biopsy test specifically for pediatric cancer patients.

This test analyzes fragments of DNA found in blood samples and has shown promising results in diagnosing various types of solid tumors in children. The study, published in npj Precision Oncology, also indicates the potential of this test in assessing treatment response and detecting possible tumor recurrence following successful initial treatment.

The liquid biopsy test developed by the CHLA and USC researchers focuses on detecting copy number alterations using low-pass whole-genome sequencing. This method is cost-effective and can analyze multiple samples simultaneously.

While it can also detect some single-nucleotide changes, it cannot detect all of them. Unlike many liquid biopsies being developed for children, this approach and similar tests by other researchers aim to identify multiple types of cancer. Thus , the market is expected to drive over the forecast period due to the above factors.

Rising Development of New Tools in Diagnosing Cancer is Expected to Drive Liquid Biopsy Market Growth

Dr. Gavin Ha, a computational biologist at the Fred Hutchinson Cancer Center, has been awarded the 2022 National Institutes of Health Director's New Innovator Award. The $1.5 million five-year grant will support Ha's research in leveraging cell-free tumor DNA in liquid biopsies to gather valuable information for cancer diagnosis, treatment selection, and disease monitoring. Liquid biopsies, which involve analyzing DNA traces in blood samples, provide molecular insights into tumors.

While most liquid biopsy strategies focus on detecting cancer-associated changes in DNA sequence, Ha takes a different approach by investigating the factors that enable DNA fragments to persist in the bloodstream, specifically examining the protection provided by DNA packaging proteins. DNA in our cells is compactly packaged, and this packaging plays a role in gene regulation. Gene expression affects how cancer cells respond to treatments, their resistance patterns, and their potential to transform into different cancer cells.

Technical Challenges and Limitations in the Liquid Biopsy are Hampering the Growth of the Global Liquid Biopsy Market

Liquid biopsy techniques face various technical challenges that can limit their effectiveness and hinder the market growth. Some of these challenges include sensitivity and specificity, standardization, and reproducibility.

Besides, regulatory and reimbursement issues can hinder the widespread adoption of liquid biopsy tests. These challenges include regulatory approvals and reimbursement policies. Thus, from the above factors, the market is expected to hamper over the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic had a significant impact on the liquid biopsy market. During the pandemic, there has been a decrease in routine healthcare visits, including cancer screenings and diagnostic procedures.

As a result, the demand for liquid biopsy tests may have been affected, as these tests are often used as non-invasive alternatives to traditional tissue biopsies. Reduced patient visits and diagnostic testing have likely resulted in a decline in the overall adoption and utilization of liquid biopsy technologies.

Moreover, many ongoing clinical trials related to liquid biopsy research and development have experienced delays or disruptions due to the pandemic. Restrictions on patient recruitment, limited access to healthcare facilities, and prioritization of resources for COVID-19 management have resulted in the postponement or alteration of clinical trial timelines. This delay in research activities can impact introducing new liquid biopsy technologies and products to the market.

As the pandemic evolves and healthcare systems adapt, the liquid biopsy market is expected to recover and continue its growth trajectory, driven by advancements in technology, research, and the increasing demand for personalized and non-invasive cancer diagnostics.

Russia-Ukraine Conflict Analysis

The Russian-Ukraine war has had implications for various sectors, including the healthcare industry and potentially the liquid biopsy market. The war has caused substantial interruptions in impacted regions' healthcare infrastructure, particularly Ukraine. Damage to medical facilities, medical supply shortages, and the relocation of healthcare staff can all interrupt the routine operation of healthcare systems.

As resources are redirected to meet more pressing healthcare needs, this interruption may impact the availability and accessibility of numerous diagnostic tests, including liquid biopsy. Moreover, the war and its economic consequences can shift healthcare expenditures and priorities. With limited budgets and a need to allocate resources to war-related efforts and post-conflict rebuilding, there may be reduced investment in healthcare infrastructure, research, and development.

The ongoing conflict can obstruct research and development endeavors in the affected regions. Constraints on funding and resources, along with an unsettled research environment, can slow the progress of innovation and scientific breakthroughs concerning liquid biopsy technologies. Additionally, collaborating and exchanging knowledge and expertise with international partners may face challenges amidst the conflict.

Segment Analysis

The Global Liquid Biopsy Market is segmented based on circulating biomarkers, products & services, applications, technology, end user, and region.

The Kits & Reagents Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The kits & reagents segment accounted for the highest market stake, accounting for approximately 43.7% of the liquid biopsy market in 2022. Liquid biopsy kits and reagents are widely adopted worldwide. This is because liquid biopsy kits and reagents are the essential components required to collect and process samples for analysis.

These kits and reagents include specific reagents, enzymes, buffers, and other materials necessary for DNA or RNA extraction, amplification, and analysis. They are designed to provide researchers and healthcare professionals with standardized and reliable tools for liquid biopsy testing.

The increasing demand for non-invasive diagnostic methods and the growing awareness of liquid biopsy's potential in cancer detection and monitoring drives the adoption of liquid biopsy kits and reagents. These kits and reagents are readily available from various manufacturers and suppliers, making them accessible to laboratories and research institutions worldwide. Thus, owing to the above factors, the market is expected to hold the largest market share in the forecast period.

Geographical Analysis

The North American Region is Dominating the Global Liquid Biopsy Market

North America is expected to dominate the nootropics market, accounting for around 38.9%. Higher investments and numerous biotechnology businesses producing the tests, high cancer prevalence, rapid technological advancements, increasing regulatory approvals, and growing government initiatives dominate the North American region.

For instance, on May 29, 2023, Guardant Health, Inc. announced that Singapore's Health Sciences Authority (HSA) had granted regulatory approval for Guardant360 CDx, a liquid biopsy test for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with advanced solid cancers. The Guardant360 CDx test was also approved as a companion diagnostic to identify patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) alterations who may benefit from treatment with TAGRISSO (osimertinib).

Furthermore, on March 22, 2023, Droplet Biosciences, a biotechnology company specializing in liquid biopsy technologies, recently secured an $8 million seed investment to develop its lymph-based liquid biopsy platform further.

The investment will support the company's efforts in advancing its proprietary technology and expanding its cancer detection and monitoring capabilities. Thus, from the above factors, the North American region is expected to hold the largest market share over the forecast period.

Competitive Landscape

The major global players in the market include: Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Exosome Sciences Inc., Grail Inc, Guardant Health, Thermo Fisher Scientific Inc., Inivata Ltd, Illumina Inc, LungLife AI Inc, and Qiagen NV among others.

Why Purchase the Report?

To visualize the Global Liquid Biopsy Market segmentation based on the circulating biomarker, product & services, application, technology, end-user, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous liquid biopsy market-level data points with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The Global Liquid Biopsy Market Report Would Provide Approximately 77 Tables, 77 Figures And 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Circulating Biomarker
3.2. Snippet by Product & Services
3.3. Snippet by Application
3.4. Snippet by Technology
3.5. Snippet by End User
3.6. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising Research in Liquid Biopsies on the Horizon for Children with Solid Cancers
  - 4.1.1.2. Rising Development of New Tools in Diagnosing Cancer
- 4.1.2. Restraints
  - 4.1.2.1. Technical Challenges and Limitations in the Liquid Biopsy
- 4.1.3. Opportunity
  - 4.1.3.1. Increasing Research Collaborations
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Circulating Biomarker

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarker
- 8.1.2. Market Attractiveness Index, By Circulating Biomarker
8.2. Circulating Tumor Cells*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Circulating Tumor DNA (ctDNA)
8.4. Cell-free DNA (cfDNA)
8.5. Extracellular Vesicles

9. By Product & Services

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Services
- 9.1.2. Market Attractiveness Index, By Product & Services
9.2. Kits & Reagents*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Instruments
9.4. Services

10. By Application

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.1.2. Market Attractiveness Index, By Application
10.2. Cancer Applications*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.2.3. Breast Cancer
- 10.2.4. Colorectal Cancer
- 10.2.5. Lung Cancer
- 10.2.6. Prostate Cancer
- 10.2.7. Liver Cancer
- 10.2.8. Other
10.3. Non-Cancer Applications
- 10.3.1. Non-Invasive Prenatal Testing (NIPT)
- 10.3.2. Organ Transplantations
- 10.3.3. Infectious Disease Testing

11. By Technology

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.1.2. Market Attractiveness Index, By Technology
11.2. Multi-gene-parallel Analysis (NGS)*
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Single Gene Analysis (PCR Microarrays)

12. By End User

12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.1.2. Market Attractiveness Index, By End User

12.2. Hospitals and Physician Laboratories*
- 12.2.1. Introduction
- 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Research Centers
12.4. Others

13. By Region

13.1. Introduction
- 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 13.1.2. Market Attractiveness Index, By Region
13.2. North America
- 13.2.1. Introduction
- 13.2.2. Key Region-Specific Dynamics
- 13.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Circulating Biomarker
- 13.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
- 13.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 13.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
- 13.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 13.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 13.2.8.1. The U.S.
  - 13.2.8.2. Canada
  - 13.2.8.3. Mexico
13.3. Europe
- 13.3.1. Introduction
- 13.3.2. Key Region-Specific Dynamics
- 13.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Circulating Biomarker
- 13.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
- 13.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 13.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
- 13.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 13.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 13.3.8.1. Germany
  - 13.3.8.2. The U.K.
  - 13.3.8.3. France
  - 13.3.8.4. Italy
  - 13.3.8.5. Spain
  - 13.3.8.6. Rest of Europe
13.4. South America
- 13.4.1. Introduction
- 13.4.2. Key Region-Specific Dynamics
- 13.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Circulating Biomarker
- 13.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
- 13.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 13.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
- 13.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 13.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 13.4.8.1. Brazil
  - 13.4.8.2. Argentina
  - 13.4.8.3. Rest of South America
13.5. Asia Pacific
- 13.5.1. Introduction
- 13.5.2. Key Region-Specific Dynamics
- 13.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Circulating Biomarker
- 13.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
- 13.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 13.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
- 13.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 13.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 13.5.8.1. China
  - 13.5.8.2. India
  - 13.5.8.3. Japan
  - 13.5.8.4. Australia
  - 13.5.8.5. Rest of Asia Pacific
13.6. Middle East and Africa
- 13.6.1. Introduction
- 13.6.2. Key Region-Specific Dynamics
- 13.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Circulating Biomarker
- 13.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
- 13.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 13.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
- 13.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

14. Competitive Landscape

14.1. Competitive Scenario
14.2. Product Benchmarking
14.3. Company Share Analysis
14.4. Key Developments and Strategies

15. Company Profiles

15.1. Bio-Rad Laboratories*
- 15.1.1. Company Overview
- 15.1.2. Product Portfolio and Description
- 15.1.3. Financial Overview
- 15.1.4. Key Developments
15.2. F. Hoffmann-La Roche AG
15.3. Exosome Sciences Inc.
15.4. Grail Inc
15.5. Guardant Health
15.6. Thermo Fisher Scientific Inc.
15.7. Inivata Ltd
15.8. Illumina Inc
15.9. LungLife AI Inc
15.10. Qiagen NV

LIST NOT EXHAUSTIVE

16. Appendix

16.1. About Us and Services
16.2. Contact Us

02-2729-4219

+886-2-2729-4219

License/价格

全球液体活检市场 - 2023-2030年

Global Liquid Biopsy Market - 2023-2030

市场概况

市场动态

对患有实体癌的儿童进行液体活检的研究不断增加，预计将推动液体活检市场的增长

诊断癌症的新工具不断发展，预计将推动液体活检市场增长

液体活检的技术挑战和限制阻碍了全球液体活检市场的发展

COVID-19影响分析

俄乌冲突分析

目录

第一章：方法和范围

第二章：定义和概述

第三章：执行摘要

第四章：动态变化

第五章：行业分析

第六章：COVID-19分析

第7章 ：俄罗斯-乌克兰战争分析

第八章：按循环生物标志物分类

第九章：按产品和服务分类

第十章：按应用分类

第十一章：按技术分类

第十二章：按终端用户分类

第十三章 ：按地区划分

第十四章：竞争格局

第十五章 ：公司简介

第16章 ：附录